Skip to content
HowShorted

NRX Pharmaceuticals, Inc. short interest in 2023

In 2023, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 1.93% of shares outstanding on 13 Jan 2023 to 3.20% on 29 Dec 2023, a change of +1.27 percentage points. The year's high was 3.20% on 29 Dec 2023 and its low 0.98% on 15 Aug 2023, averaging 1.90% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.56 days on 28 Apr 2023. Full history: NRX Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for NRX Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
1.93% (13 Jan 2023)
End of year
3.20% (29 Dec 2023)
Change
+1.27 pp
High
3.20% (29 Dec 2023)
Low
0.98% (15 Aug 2023)
Average
1.90%
Highest days to cover
20.56 (28 Apr 2023)
SEC filings marked
6

Every report in 2023

NRX Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20231.93%3.49
31 Jan 20231.75%4.25
15 Feb 20231.69%7.59
28 Feb 20231.84%12.46
15 Mar 20232.09%6.85
31 Mar 20232.24%8.4710-K filed, results (8-K)
14 Apr 20232.22%11.43
28 Apr 20232.16%20.56
15 May 20231.92%10.1710-Q filed
31 May 20231.80%10.75
15 Jun 20231.67%1.15
30 Jun 20231.25%3.51
14 Jul 20231.71%2.69
31 Jul 20231.50%3.32
15 Aug 20230.98%1.6110-Q filed
31 Aug 20231.76%1.00
15 Sep 20231.79%1.00
29 Sep 20232.62%3.18
13 Oct 20232.32%2.79
31 Oct 20231.92%4.12
15 Nov 20231.83%4.2810-Q filed, results (8-K)
30 Nov 20231.75%5.29
15 Dec 20231.59%5.69
29 Dec 20233.20%1.00

See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.